Hanall Biopharma Co., Ltd.(KR:009420)
₩51,100.000.00 (0.00%)
KR:009420
Hanall Biopharma Co., Ltd. financials statements
₩51,100.00
At close:0.00 (0.00%)
Want to see KR:009420 full AI Analyst Report?
Hanall Biopharma Co., Ltd. (009420) Income Statement
Hanall Biopharma Co., Ltd. Income Statement
Last quarter (Q2 2026), Hanall Biopharma Co., Ltd.'s total revenue was ₩44.28B, an increase of 8.84% from the same quarter last year. In Q2, Hanall Biopharma Co., Ltd.'s net income was ₩-19.23B. See Hanall Biopharma Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ₩ 155.18B | ₩ 138.94B | ₩ 134.91B | ₩ 110.00B | ₩ 101.59B | |
| ₩ 79.10B | ₩ 73.31B | ₩ 75.04B | ₩ 61.97B | ₩ 60.33B | |
| ₩ 80.71B | ₩ 73.08B | ₩ 71.98B | ₩ 59.15B | ₩ 50.23B | |
| Depreciation and Amortization | ₩ 3.55B | ₩ 3.12B | ₩ 3.25B | ₩ 3.05B | ₩ 2.72B |
| ₩ 1.94B | ₩ 3.35B | ₩ 6.58B | ₩ 5.05B | ₩ 11.45B | |
| ₩ -1.61B | ₩ 230.47M | ₩ 3.06B | ₩ 1.51B | ₩ 10.10B | |
| ₩ -4.57B | ₩ -260.70M | ₩ 146.47M | ₩ 423.64M | ₩ -1.40B | |
| ₩ -6.18B | ₩ -30.23M | ₩ 3.20B | ₩ 1.93B | ₩ 8.70B | |
| ₩ -5.56B | ₩ -1.80B | ₩ 3.51B | ₩ 251.47M | ₩ 8.90B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ -111.55 | ₩ -35.59 | ₩ 69.21 | ₩ 4.95 | ₩ 173.74 |
| Diluted EPS | ₩ -111.55 | ₩ -35.59 | ₩ 69.21 | ₩ 4.95 | ₩ 173.74 |
| Weighted Average Shares Outstanding | 49.83M | 50.71M | 50.69M | 50.82M | 51.20M |
| Weighted Average Shares Outstanding (Diluted) | 49.83M | 50.71M | 50.69M | 50.82M | 51.20M |
Currency in KRW
